Skip to main content
. Author manuscript; available in PMC: 2024 Mar 2.
Published in final edited form as: Cancer Chemother Pharmacol. 2023 Mar 2;91(3):281–290. doi: 10.1007/s00280-023-04511-0

Table 4.

All (related and unrelated) cardiac adverse events

Adverse event All grades
Number of
patients (%)
Grades 3–4
Number of
patients (%)
Atrial fibrillation 2 (10) 1 (5)
Atrial flutter 1 (5) 0 (0)
Cardiac arrest 2 (10) 2 (10)
Non-specific ST and/or T wave changes 3 (15) 0 (0)
Cardiac troponin I increased 2 (10) 2 (10)
Cardiac troponin T increased 1 (5) 1 (5)
Chest pain, cardiac 2 (10) 1 (5)
Conduction disorder 1 (5) 0 (0)
Electrocardiogram QTc prolonged 17 (85) 2 (10)
Myocardial infarction 1 (5) 1 (5)
Pericardial effusion 1 (5) 0 (0)
Pericarditis 1 (5) 0 (0)
Sinus bradycardia 2 (10) 0 (0)
Sinus tachycardia 11 (55) 0 (0)
Ejection fraction decreased 1 (5) 0 (0)
Acute coronary syndrome 1 (5) 0 (0)
Pericardial tamponade 1 (5) 1 (5)